The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 334:724-726 March 14, 1996 Number 11
NextNext

Low-Molecular-Weight Heparin — An Opportunity for Home Treatment of Venous Thrombosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Venous thromboembolism, a disease now recognized in most cases to have a genetic basis,1 is the discharge diagnosis of more than a quarter-million patients in U.S. hospitals annually.2 Heparin has been the standard initial therapy for this condition since the 1940s. For many years, evidence of the efficacy of heparin in these patients was based on experimental studies in animals and uncontrolled clinical experience. Not until 1992 did a randomized, double-blind trial demonstrate that patients with deep-vein thrombosis do indeed require initial treatment with full-dose heparin.3

Admission to the hospital has been deemed necessary for patients with deep-vein thrombosis in . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.